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Cimetidine has been shown to have beneﬁcial effects in colorectal cancer patients. In this study, a total of 64 colorectal cancer
patients who received curative operation were examined for the effects of cimetidine treatment on survival and recurrence.
The cimetidine group was given 800 mg day
71 of cimetidine orally together with 200 mg day
71 of 5-ﬂuorouracil, while the
control group received 5-ﬂuorouracil alone. The treatment was initiated 2 weeks after the operation and terminated after 1
year. Robust beneﬁcial effects of cimetidine were noted: the 10-year survival rate of the cimetidine group was 84.6% whereas
that of control group was 49.8% (P50.0001). According to our previous observations that cimetidine blocked the expression
of E-selectin on vascular endothelium and inhibited the adhesion of cancer cells to the endothelium, we have further stratiﬁed
the patients according to the expression levels of sialyl Lewis antigens X (sL
x) and A (sL
a). We found that cimetidine
treatment was particularly effective in patients whose tumour had higher sL
x and sL
a antigen levels. For example, the 10-year
cumulative survival rate of the cimetidine group with higher CSLEX staining, recognizing sL
x, of tumours was 95.5%, whereas
that of control group was 35.1% (P=0.0001). In contrast, in the group of patients with no or low levels CSLEX staining,
cimetidine did not show signiﬁcant beneﬁcial effect (the 10-year survival rate of the cimetidine group was 70.0% and that of
control group was 85.7% (P=n.s.)). These results clearly indicate that cimetidine treatment dramatically improved survival in
colorectal cancer patients with tumour cells expressing high levels of sL
x and sL
a.
British Journal of Cancer (2002) 86, 161–167. DOI: 10.1038/sj/bjc/6600048 www.bjcancer.com
ã 2002 The Cancer Research Campaign
Keywords: colorectal cancer; cancer metastasis; sialyl Lewis antigens; cell adhesion; cimetidine
We demonstrated in a previous randomized control study that
cimetidine, a histamine type 2 receptor antagonist, was signiﬁcantly
advantageous in increasing the disease-free period and survival of
these patients (Matsumoto, 1995). Cimetidine was given to color-
ectal cancer patients receiving 5-ﬂuorouracil (5-FU) after
operation with the aim of reducing appetite loss and reﬂux esopha-
gitis. Two other study groups reported similar advantageous effect
of cimetidine on colorectal cancer patients (Adams and Morris,
1994; Svendsen et al, 1995). Furthermore, treatment with cimeti-
dine was reported to be beneﬁcial for patients with gastric cancer
(Tonnesen et al, 1988), melanoma (Creagnan et al, 1985; Hell-
strand et al, 1994) or renal cell cancer (Sagaster et al, 1995).
Several studies have suggested various mechanisms underlying
the beneﬁcial effect of cimetidine on cancer patients, such as the
following: (i) reversal of the pharmacological activity of histamine,
tumour growth promoter by blocking histamine receptors on
cancer cells (Adams et al, 1994; Reynolds et al, 1996) or affecting
histamine metabolism (Garcia-Caballero et al, 1994); (ii) acting
as an antioxidant, thus inhibiting tumour growth (Kimura et al,
1986) and (iii) augmentation of anticancer immune reactivity
through receptor antagonism of circulatory suppressor T cells
(Kumar, 1990), prevention of postoperative alterations of lympho-
cyte subpopulations (Hansbrough et al, 1986), or by maintenance
of natural killer cell activity (Katoh et al, 1996). In our study, we
found that cimetidine could block the expression of E-selectin on
the surface of human umbilical vein endothelial cells, thus blocking
the tumour cell adhesion to endothelium and preventing the liver
metastasis in nude mice model (Kobayashi et al, 2000). Such ﬁnd-
ings were not known when we had planned this prospective
randomized control study. But now, it is known that sialyl
Lewis-X (sL
x) and sialyl Lewis-A (sL
a) antigens are ligands to E-
selectin, and sL
x and sL
a expressed on cancer cells mediate adhe-
sion of the cancer cells to vascular endothelial cells expressing E-
selectin (Phillips et al, 1990; Takada et al, 1991, 1993). The adhe-
sion of cancer cells to vascular endothelial cells is a key step in
invasion and metastasis of cancer cells (Hoff et al, 1989, 1990;
Nakamori et al, 1993). Therefore, we decided to classify the
subjects according to the level of expression of sL
x and sL
a on
cancer cells and we investigated 10-year survival that was the major
objects of this clinical study. We examined whether the effect of
cimetidine on cancer patients was correlated with the degree of
expression of sL
x and sL
a on tumour cells in 61 colorectal cancer
patients in our randomized control study (Matsumoto, 1995).
Treatment with cimetidine markedly reduced the incidence of
metastasis and signiﬁcantly increased survival during a follow-up
period of more than 10 years in patients whose tumour cells
expressed sL
x and sL
a epitopes at increased levels.
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Patients
This randomized control study was performed on colorectal
cancer patients in a multicentre clinical trial of cimetidine. The
clinical trial was conducted through the collaboration of 15 insti-
tutions in Japan listed at the end of the text. The coordination
centre for the trial was the Department of Surgery, Second
Teaching Hospital, School of Medicine, Fujita Health University.
It was carried out with the approval of Fujita Health University
Ethical Committee. A total of 72 patients who were diagnosed
colorectal cancer by histological examination and had a primary
tumour of T2 or T3 were enrolled after excluding patients who
previously received chemotherapy, radiotherapy or immunother-
apy and those who had multiple cancers or severe
complications. Out of the 72 selected, patients who did not
undergo curative resection (two patients), those who did not
receive adequate drug administration (three patients), and whose
disease stage was considered inappropriate for the trial (three
patients) were further considered ineligible. These ineligible
patients were equally distributed between the treatment groups
and were excluded from the analysis. All patients were randomly
allocated and there were none lost to follow-up. All 64 eligible
patients gave informed consent to take part in the clinical trial
and were enrolled for the trial from March 1990 to April 1992
(Table 1). The patients were followed up until the end of May
2000, with a mean follow-up term of 10.7 years. During the
follow-up period, the patients were checked at least twice a year
for occurrence of metastasis as well as for blood chemistry, X-
ray, ultrasonography and computed tomography. Survival was
the primary endpoint. Time to recurrence (disease-free period)
was also assessed.
Treatment of the patients
The 64 patients were classiﬁed into two groups consisting of 34
and 30 for the treatment and control group, respectively. There
were no differences in age, sex, clinical characteristics and macro-
scopic shape, size, location, stage and pathological type of the
cancer between the two groups (Table 1). All patients received
curative resection of the cancer and within 24 h of the resection,
were intravenously injected with 8 mg m
72 of mitomycin C
(Kyowa Hakko, Inc, Tokyo, Japan). The patients in the cimetidine
group (n=34) were given 800 mg day
71 of cimetidine orally
(SmithKline Beecham, Co., Tokyo, Japan) together with 200 mg
day
71 of 5-FU orally (Kyowa Hakko, Inc.), while patients in the
control group (n=30) received 5-FU alone. Treatment for both
groups started 2 weeks after the operation and was given for 1 year.
Immunostaining of sL
x and sL
a on cancer cells
Cancer tissues, which had been resected by the curative operation
and embedded in parafﬁn, were used for immunostaining of sL
x
and sL
a. A total of 61 specimens were processed since we lost
the specimens of two patients in the treatment group and of one
patient in the control group. Immunostaining was performed by
the avidin biotin complex method. Three different anti-sL
x mono-
clonal antibodies (mAbs), CSLEX (Signet Lab., Dedham, MA,
USA) (Fukushima et al, 1984), KM93 (Kyowa Hakko, Inc) (Shirata
et al, 1987) and FH6 (Otsuka Pharmaceutical Co., Osaka, Japan)
(Fukushi et al, 1984) were used. The CA19-9 mAb (CIS Bio Inter-
national, Cedex) (Charpin et al, 1982) was used as the anti-sL
a
mAb. Cancer tissues in parafﬁn blocks were sectioned. The sections
were deparafﬁnized in xylene, dehydrated through graded concen-
trations of ethanol and washed with distilled water. After treatment
of the sections with bovine serum albumin to block nonspeciﬁc
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Table 1 Characteristics of colorectal cancer patients in the cimetidine group and control
group
Cimetidine group Control group
(n=34) (n=30) P value
Gender
Male 20 15 0.479
Female 14 15
Median (range) age in years 60 (43–74) 57 (25–74) 0.180
Mean size 52.0 53.6 0.841
Macroscopic type
a
Protuberant type 2 4 0.550
Ulcerated type with clear margin 26 23
Ulcerated type with inﬁltration 5 3
Others 1 0
Location
Colon 27 19 0.175
Rectum 7 11
Pathological type
Well differentiated adenocarcinoma 24 22 0.691
Moderately differentiated adenocarcinoma 8 6
Poorly differentiated adenocarcinoma 1 0
Mucinous adenocarcinoma 1 2
Histological stage
a
1 2 3 0.524
21 8 1 3
31 1 8
43 6
Dukes’ stage
A 2 3 0.701
B1 9 1 4
C1 3 1 3
aJapanese classiﬁcation according to Japanese Society for Cancer of the Colon and Rectum.
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one of the anti-sL
x mAbs or the anti-sL
a mAb for 2 h. The sections
were rinsed with phosphate buffered saline (PBS), and then incu-
bated in biotinylated anti-mouse immunoglobulin serum (Vector
Lab, Burlingame, CA, USA ) for 30 min. After washing with
PBS, the sections were immersed in 0.3% (wt/vol) hydrogen perox-
ide in absolute methanol for 20 min to block endogenous
peroxidase. The sections were again washed with PBS and incu-
bated in avidin-conjugated horseradish peroxidase (Vector Lab)
for 30 min, and then washed with PBS. Finally, the sections were
incubated in peroxidase substrate solution until the desired stain
intensity had developed (1 to 5 min). After washing with distilled
water, the sections were counterstained with hematoxylin, dehy-
drated in ethanol, washed in xylene and mounted.
Determination of degree of sL
x and sL
a expression on
cancer cells
By microscopic observation of the predominant area of the cancer
tissue in the immunostained section, the percentage of positively
stained cancer cells was calculated. Two pathologists observed the
specimens and determined degrees of sL
x and sL
a expression. The
degrees of expression of sL
x and sL
a based on the percentage of
positively stained cancer cells were presented as follows: level 0,
no stained cancer cells; level 1, less than 5% cancer cells stained;
level 2, 5–70% cancer cells stained; level 3, 71% or more cancer
cells stained. We deﬁned the classiﬁcation of patients according
to the degree of sLe
x and sLe
a expression as such based on our
observations that the number of cases with tumours exhibiting
low-positively staining cancer cells in each category was very few.
For example, among the cases with level 2 for CSLEX, 19 out of
21 cases (90%) exhibited the tumour more than 30% positively
stained cancer cells and similarly, among the cases with level 2
expression of KM93, all 24 cases (100%) exhibited the tumour with
over 60% positively stained cancer cells. In addition, 95% of the
cases deﬁned as level 2 for CA19-9 exhibited over 30% of positively
stained cancer cells. There was no case exhibited where the tumour
tissue with less than 10% stained cancer cells with any of the sialyl
Lewis antigens.
Statistical analyses
Cumulative survival rate was calculated by the Kaplan-Meier
method. Statistical signiﬁcance of the difference in the survival rate
of patients between two categories was evaluated by the log rank
test or the generalized Wilcoxon test. Differences in metastasis
frequency were calculated by Fisher’s exact t-test. A P value of
50.05 was considered signiﬁcant.
RESULTS
Cimetidine treatment increases survival of colorectal
cancer patients
Among the 64 patients with curative operation, 34 cases were
classiﬁed into the cimetidine group (800 mg day
71 of cimetidine
orally for 1 year) and 30 cases served as the control group (without
cimetidine treatment). All the patients were treated with 5-FU
(200 mg day
71) for 1 year. In order to evaluate the effect of cime-
tidine, the survival rates were compared between these two groups
(Figure 1). The cumulative 10-year survival rate of the cimetidine
group (n=34) was 84.6%, whereas that of control group (n=30 )
was 49.8% (P=0.0015 by log rank test and P=0.0010 by generalized
Wilcoxon test).
We then evaluated the effects of cimetidine according to the
clinical stage of colorectal cancer. As shown in Figure 2, the effect
of cimetidine on the survival of patients with involvement of re-
gional lymph nodes, thus classiﬁed as Dukes C, was remarkably
signiﬁcant. The cumulative 10-year survival rate of the cimetidine
group of Dukes C patients (n=13) was 84.6%, whereas that of
the control group (n=13) was 23.1% (P=0.0016 by log rank test;
P=0.0026 by generalized Wilcoxon test). In contrast, the effect of
cimetidine on the survival of patients at Dukes A or B classiﬁcation
were not statistically signiﬁcant, although there was some beneﬁcial
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Figure 1 Effect of cimetidine on the survival of patients with colorectal cancers. Patients who were treated with cimetidine and 5-FU (‘cimetidine’ group)
and 5-FU alone (‘control’ group) were compared by Kaplan-Meier method. The cumulative 10-year survival rate of the cimetidine group (n=34) was 84.6%,
whereas that of control group (n=30) was 49.8% (P=0.0015 by log rank test and P=0.0010 by generalized Wilcoxon test).
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(2), 161–167tendency for the cimetidine group (the cumulative 10-year survival
rate of the cimetidine group (n=21) was 90.5%, whereas that of the
control group (n=17) was 69.5% (not signiﬁcant both by log rank
and the generalized Wilcoxon tests).
Cimetidine reduces frequency of metastasis in colorectal
cancer patients
The incidence of new metastasis in colorectal cancer patients over a
period of 10 years after curative resection of the tumour was
compared between the two study groups; the cimetidine group
(treated with cimetidine and 5-FU) and a control group (treated
with 5-FU alone). In the cimetidine group (n=34), eight metastases
occurred in seven patients, whereas in the control group (n=30), 23
metastases occurred in 16 patients. The frequency and location of
metastases in these colorectal cancer patients are shown in Table 2.
Overall incidence of metastasis was signiﬁcantly reduced in the
cimetidine (P=0.0060 by Fisher’s t-test).
Cimetidine treatment increases survival of colorectal
cancer patients with high-level sL
x or sL
a epitope
expression on tumour cells
Expression of sL
x and sL
a on cancer cells was determined by immu-
nostaining of tumour tissues with anti-sL
x and anti-sL
a monoclonal
antibodies (mAbs). The patients were grouped according to the
level of expression of sL
x or sL
a on their tumour cells as described
in Materials and methods.
The effect of cimetidine on the survival of patients was evaluated
with regard to the level of sL
x and sL
a antigens. The cumulative
survival rates of patients, with or without cimetidine, based on
the CSLEX epitope expression were demonstrated in Figure 3A.
In patients with high CSLEX expression (levels 2 or 3), the cumu-
lative 10-year survival rate of the cimetidine group (n=22) was
95.5% whereas that of control group (n=22) was 35.1%
(P=0.0001 by log rank test and generalized Wilcoxon test). In
contrast, patients with no (level 0) or low (level 1) CSLEX expres-
sion, the cumulative 10-year survival rate of the cimetidine group
(n=10) was 70.0 and 85.7% for the control group (n=7), (not
signiﬁcant by log rank and generalized Wilcoxon tests).
Cimetidine had a similar positive effect on the survival rate of
patients with high-level KM93 sL
x or CA19-9 sL
a epitopes expres-
sion on their tumours. The results of survival based on KM93 mAb
expression were shown in Figure 3B. In patients with high KM93
expression, the cumulative 10-year survival rate of the cimetidine
group (n=25) was 88.0%, whereas that of the controls (n=22)
was 35.1% (P=0.0001, log rank test; P=0.0002, generalized Wilcox-
on test). In contrast, in patients with low level or no KM93
expression, the cumulative survival rates were equal for the cimeti-
dine group (n=7) and the control group (n=7) (85.7% for both).
Similarly, the results of survival according to CA19-9 mAb
expression were shown in Figure 3D. In patients with high level
of sL
a expression, the cimetidine treatment was effective: the cumu-
lative 10-year survival rate for the cimetidine (n=22) and the
control (n=18) groups were 90.9 and 20.1%, respectively
(P=0.0001). However, for patients with no or low level sL
a expres-
sion, there was no beneﬁcial effect of the cimetidine treatment:
cumulative 10-year survival rate for the cimetidine group (n=11)
was 80.0 and 90.9% for the control group (statistically not signiﬁ-
cant).
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Figure 2 Effect of cimetidine on the survival of patients with colorectal cancer according to the Dukes classiﬁcation. Dukes A and B, localized cancer
limited to mucosa and submucosa (A) and extending through serosa without lymph node metastasis (B). Dukes C, cancers involving regional lymph nodes.
Note that the beneﬁcial effects of cimetidine were greater in patients with Dukes C: the cumulative 10-year survival rate of the cimetidine group (n=13) was
84.6%, whereas that of control group (n=13) was 23.1% (P=0.0016 by log rank test and P=0.0026 by generalized Wilcoxon test).
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correlated with the level of sL
x and sL
a epitopes. As shown in
Figure 3C, using FH6 mAb recognizing one of the sL
x epitopes, the
beneﬁcial effect of cimetidine treatment was evident irrespective of
the level of FH6. In patients with high-level FH6 expression, the
cumulative 10-year survival rate of the cimetidine (n=17) and
the controls (n=15) groups were 88.2 and 44.4%, respectively
(P=0.0224, log rank test; P=0.0191, generalized Wilcoxon test).
In addition, even in patients with low level or no FH6 expression,
the beneﬁcial effects of cimetidine on the patients survival were
signiﬁcant: the cumulative 10-year survival rate for the cimetidine
(n=15) and the control (n=7) group were 86.7 and 50.0%
(P=0.03520, log rank test; P=0.0390, generalized Wilcoxon).
DISCUSSION
Adhesion of cancer cells via their sL
x or sL
a antigen to E-selectin
on vascular endothelium is considered to lead to metastasis. Based
on our recent observations that cimetidine blocked in vitro expres-
sion of E-selectin on the surface of vascular endothelial cells as
reported by Kobayashi et al., we examined in this study whether
the beneﬁcial effect of cimetidine on colorectal cancer patients
was dependent on the degree of expression of sL
x and sL
a on the
tumour cells.
In the control group patients (treated with 5-FU alone after cura-
tive operation) of these studies, we noticed that the patients with
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Table 2 Frequency and location of metastasis in colorectal cancer
patients in the cimetidine group
a and control group
b
Frequency of metastasis
Cimetidine group Control group
Location of metastasis (n=34) (n=30)
Liver 3 3
Lung 2 7
Bone 0 1
Brain 0 2
Local metastasis or region of anastomosis 2 5
Para-aortic LN
c 02
Left supra clavicular LN 0 1
Peritoneum 1 1
Ovarium 0 1
Total 8
d 23
e
a34 colorectal cancer patients who received cimetidine and 5-FU after curative resec-
tion of tumour.
b30 colorectal cancer patients who received 5-FU alone after curative
resection of tumour.
cLN: lymph node.
d8 metastases occurred in seven patients.
e23
metastases occurred in 16 patients.
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Figure 3 Effect of cimetidine on cumulative survival rates in the colorectal cancer patients. The tumour tissues from individual patients obtained during
curative operations were stained by mAbs to sL
x antigen, including CSLEX (A), KM93 (B), FH6 (C) and sL
a antigen, CA19-9 (D). The level of these epitope
expression were semi-quantitated upon microscopic examination by two experienced pathologists: level 1, less than 5% cancer cells stained; level 2, 5–70%
cancer cells stained; level 3, 71% or more cancer cells stained. The survival rates of patients with cimetidine treatment (‘Cimetidine’) or without cimetidine
treatment (‘Control’) were compared using Kaplan-Meier method. The number of patients (‘n’) in each category was indicated in the ﬁgure. The statistical
signiﬁcance was evaluated by log rank test and generalized Wilcoxon test.
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x and sL
a antigens at higher levels showed a
markedly higher frequency of metastasis and a signiﬁcantly lower
survival rate, indicating its aggressive characteristics. These results
largely agree with Nakamori et al (1993) who reported that colonic
cancers expressing the sL
x epitopes recognized by FH6 mAb at higher
levels were more malignant. In our study, however, malignancy of the
cancer was related to the expression of sL
x epitopes recognized by
CSLEX and KM93 mAbs, but not to the expression of sL
x epitope
recognized by FH6 mAb. The reason for this discrepancy might
depend on different binding property of these three monoclonal anti-
bodies to the epitopes of tumour cells (Charpin et al, 1982; Dohi et al,
1993). If the epitope, which was recognized with FH6 mAb, reacted
with E-selectin with high intensity, cimetidine could inhibit sticking
of the tumour cells to endothelial cells. Our results also indicated that
colorectal cancer expressing the sL
a epitope recognized by the CA19-9
mAb at higher levels appeared to be as aggressive as those expressing
the sL
x epitope.
The fact that elevated expression of the sL
x epitopes recognized
by the CSLEX or KM93 mAbs and the sL
a epitope recognized by
the CA19-9 mAb were associated with more aggressive nature of
colorectal cancer malignancy suggested the importance of these
epitopes as ligands for E-selectin. To deﬁne the sL
x and sL
a
epitopes that were important E-selectin ligands, Srinivas et al
(1996) determined the blocking activity of several anti-sL
x and
anti-sL
a mAbs on the adhesion of human colonic cancer cell lines
to human vascular endothelial cells in vitro.
They reported that anti-sL
x CSLEX and KM93 mAbs did not
block adhesion, probably because of the very low levels of sL
x
expression in the cancer cell lines detected by Western blotting,
and that the anti-sL
a CA19-9 mAb blocked adhesion of one cancer
cell line but not that of another cancer cell line. Phillips et al
(1990) demonstrated that anti-sL
x CSLEX mAb blocked adhesion
of a human promyelocytic cell line to human endothelial cells.
These results indicated the complexity of expression and function
of sL
x and sL
a epitopes on the established cell lines. However, it
is conceivable that down regulation of E-selectin, a ligand for sL
x
and sL
a antigens, by cimetidine can block some of the malignant
phenotype of cancer as predicted by our recent study (Kobayashi
et al, 2000).
The present study clearly demonstrated that the beneﬁcial effect
of cimetidine given together with 5-FU after a curative operation
on colorectal cancer patients depended on the degree of expression
of the sL
x and sL
a epitopes on tumour cells. Treatment with cime-
tidine markedly reduced the frequency of metastasis and
signiﬁcantly increased survival rate in the patients whose cancer
cells expressed higher levels of the sL
x and the sL
a epitopes, but
not in the patients whose cancer cells expressed none or lower
levels of these epitopes, although such a cancer was considered
to be less aggressive. Colorectal cancer cells expressing higher levels
of sL
x and sL
a should adhere easily to vascular endothelium expres-
sing E-selectin, and this would then result in metastasis, a marker
of malignancy. If cimetidine given to the patients blocked the
expression of E-selectin on vascular endothelial cells, even malig-
nant colorectal cancer cells expressing higher levels of sL
x and
sL
a would not be able to adhere to such vascular endothelial cells.
In this situation, the frequency of metastasis in the patients would
be reduced and the survival rate of the patients increased. Taken
together, these results suggested a mechanism underlying the bene-
ﬁcial effect of cimetidine on colorectal cancer patients, presumably
by blocking the expression of E-selectin on vascular endothelial
cells and inhibiting the adhesion of cancer cells.
These results with cimetidine suggest that the cognate interac-
tion of sL
x and sL
a antigens with E-selectin provides a novel
target for prevention of cancer progression. It is likely that cimeti-
dine treatment may also be effective for a range of other sL
x- and
sL
a-expressing tumours, such as oesophageal, gastric, pulmonary,
pancreatic, biliary tract, uterine, ovarian and breast cancer. Our
study was so small a number scale that further large-scale study
should be investigated to assess the effect of cimetidine to colon
cancer with high expression of sialyl Lewis antigens.
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